drugset / Trial / NCT02728830
A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers
NaSingle-groupOpen-labelTreatment
Summary
The ultimate goal of the study is to identify potential biomarkers, immune gene expression signatures, and co-stimulatory pathways that may be used to understand the effect of immune checkpoint inhibitors on gynecologic cancers.
Timeline
- Start
- 2016-06
- Primary completion
- 2019-01-31
- Completion
- 2022-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |